Congenital Amegakaryocytic Thrombocytopenia
A rare inherited bone marrow failure syndrome present from birth, caused by MPL gene mutations that impair platelet production and often progress to full marrow failure.
- Present at Birth
- MPL Gene-Related
- Curative Transplant Pathways
- Most Common In
- Newborns and infants
- Clinical Hallmark
- Severe thrombocytopenia at birth, absent marrow megakaryocytes
- Affected Gene
- MPL
- Advanced Therapies
- Hematopoietic Stem Cell Transplant
Condition Overview
Congenital Amegakaryocytic Thrombocytopenia (CAMT) is a rare, inherited bone marrow failure syndrome that presents at birth or in early infancy with severely low platelet counts due to an absence of megakaryocytes, the bone marrow cells responsible for producing platelets.
CAMT is caused by mutations in the MPL gene, which encodes the receptor for thrombopoietin, the hormone that drives platelet production. Without functional MPL signaling, megakaryocyte development fails, and over time the bone marrow's broader ability to produce all blood cell types can also decline, leading to aplastic anemia.
Early recognition is essential because most children with CAMT will eventually require a stem cell transplant to achieve durable correction of their blood counts.
Types and Subtypes
CAMT is classified based on the specific MPL gene mutation and the resulting clinical course.
Symptoms and Signs
CAMT typically presents at birth or within the first weeks of life with bleeding-related symptoms due to severely low platelet counts.
Causes and Risk Factors
CAMT is caused entirely by inherited genetic mutations; there are no known environmental or lifestyle risk factors.
Diagnosis and Investigations
Diagnosis combines early clinical presentation with bone marrow evaluation and genetic confirmation, typically coordinated by a pediatric hematologist.
Disease Course Classification
CAMT does not use a tumor staging system; instead, disease course is tracked by the degree of marrow failure progression, which guides the timing of transplant.
Standard Treatment Options
Management evolves over the disease course, moving from supportive transfusion care toward definitive treatment with stem cell transplant.
Advanced and Emerging Treatment Options
Stem cell transplant remains the cornerstone curative therapy, with research exploring gentler conditioning regimens and gene-based alternatives.
Cellular Therapy
Hematopoietic Stem Cell Transplant (HSCT)
Transplant from a matched sibling, unrelated, or haploidentical donor corrects the underlying marrow failure and is the established curative treatment.
Reduced-Intensity Conditioning
Reduced-Toxicity Transplant Regimens
Newer conditioning protocols aim to reduce long-term transplant-related toxicity, particularly important in young infants.
Gene Therapy
Investigational MPL Gene Correction
Early-stage research is exploring gene-correction approaches as a potential future alternative to donor-dependent transplant.
Biomarkers and Precision Medicine
Specific laboratory and genetic markers help confirm CAMT, distinguish it from other causes of neonatal thrombocytopenia, and track disease progression.
When a Second Opinion May Be Important
Given the rarity of CAMT and the importance of transplant timing, specialist input is valuable at several stages.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Without treatment, CAMT typically progresses to severe aplastic anemia. With timely stem cell transplant, however, many children achieve durable correction of their blood counts and go on to thrive.
Supportive Care and Living With CAMT
Supportive care focuses on minimizing bleeding and infection risk while monitoring for disease progression and planning toward transplant.
How CancerFax Helps You Explore Treatment Options
CancerFax helps families navigate a CAMT diagnosis by coordinating specialist review of marrow biopsy and genetic results, second opinions on transplant timing, and connections to experienced pediatric transplant centers.
Get a free case reviewFrequently Asked Questions
CAMT is a rare inherited bone marrow failure syndrome present at birth, caused by MPL gene mutations that prevent normal platelet production and often progress to failure of all blood cell lines.
The first signs are usually bleeding-related, such as petechiae, bruising, or bleeding from the umbilical stump or injection sites, noticed shortly after birth.
CAMT is caused by inherited mutations in the MPL gene, which is needed for the bone marrow to produce megakaryocytes and platelets.
Diagnosis involves blood counts, bone marrow biopsy showing absent megakaryocytes, elevated thrombopoietin levels, and genetic testing confirming MPL mutations.
Most children with CAMT eventually develop broader marrow failure affecting all blood cell types, though the timing varies between Type I and Type II disease.
Hematopoietic stem cell transplant from a matched donor can be curative and is the standard definitive treatment for CAMT.
Supportive care, including platelet and red cell transfusions and infection precautions, is used to manage symptoms while monitoring disease progression.
No. While CAMT shares some features with conditions like Fanconi anemia, it is distinguished by its specific MPL gene cause and characteristic absence of megakaryocytes.
Yes, genetic counseling is recommended to help parents understand recurrence risk for future pregnancies given the autosomal recessive inheritance pattern.
Yes. CancerFax can help review your child's medical reports, coordinate a second opinion on transplant timing, and connect your family with pediatric transplant centers experienced in treating CAMT.
Get Expert Guidance on a CAMT Diagnosis
CancerFax can help connect your family with specialist review and transplant centers experienced in treating CAMT.